Chapter 27 — Further Reading

Peptides in Oncology: Hormone-Axis Blockade, Somatostatin Analogs, and Radioligand Therapy

A note on searching this literature. Oncology is unusually well organized: the pivotal trials have names, the guidelines are public, and the labels are freely available from regulators. That means you can almost always get to a primary source, and you should — this is one of the few areas in this book where the evidence is not hard to find, only hard to read carefully.

A second note. Some of this material concerns treatments that readers or their families may be receiving. Reading a trial report is not the same as receiving medical advice, and the eligibility criteria in a published paper are not a statement about any individual. Chapter 39 is about making the conversation with a clinician useful; nothing here substitutes for it.

Tier 1 — Start here

The pivotal trial reports themselves. These are more readable than their reputation suggests, and the eligibility criteria section is where the real education is.

• NETTER-1 — Strosberg J, et al. "Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors." New England Journal of Medicine, 2017. Read the eligibility criteria before the results, then read the results, then re-read the criteria. Follow up with the long-term overall survival analysis, which is where the honest complication of this story lives.
• VISION — Sartor O, et al. "Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer." New England Journal of Medicine, 2021. Note how the PSMA-PET screening step functions as part of the trial design rather than as a preliminary.
• CLARINET — Caplin ME, et al. "Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors." New England Journal of Medicine, 2014. A clean, placebo-controlled demonstration of an antiproliferative claim, with a progression-free endpoint clearly labeled as such.
• PROMID — Rinke A, et al. Reported in the Journal of Clinical Oncology, 2009. Small, and important for exactly that reason: a modest trial that changed practice because it asked a narrow question well.

Regulatory labels. Pull the current prescribing information for lutetium Lu 177 dotatate, lanreotide, and degarelix directly from the FDA or EMA. Read the INDICATIONS section aloud and count the qualifying clauses. This is the single most useful thirty minutes available for the Dossier work in this chapter.

Clinical practice guidelines. The NCCN guidelines (United States) and ESMO guidelines (Europe) for neuroendocrine tumors and for prostate cancer show how these agents are actually sequenced. Guidelines are also where you can see the difference between "approved" and "recommended," which are not the same thing and are constantly conflated.

Tier 2 — Going deeper

On the endocrine history.

• Charles Huggins' 1966 Nobel Lecture, Endocrine-Induced Regression of Cancers, is short, free, and still one of the clearest statements of the idea that a cancer can depend on its host's hormones.
• The 1977 Nobel Prize materials for Roger Guillemin and Andrew Schally cover the isolation of GnRH and somatostatin. Worth reading for a sense of how difficult it was to get from "there is a factor" to "here is the sequence."

On somatostatin analogs and neuroendocrine tumors.

• Review articles on somatostatin receptor subtypes (SSTR1–5) and their differential expression across tumor types. This is the material that explains why receptor-targeted approaches work in some neuroendocrine tumors and not others.
• Literature on carcinoid syndrome management, including carcinoid crisis. Useful for seeing how much of this therapy's value is symptom control that never appears in a survival curve.

On radioligand therapy and theranostics.

• Reviews of ¹⁷⁷Lu dosimetry and renal protection. The amino acid co-infusion is a nice worked example of engineering around a known biodistribution problem.
• Literature on ⁶⁸Ga-dotatate and PSMA PET imaging agents, which is where the diagnostic half of the theranostic pair lives.
• Reviews of alpha-emitting radionuclides (notably actinium-225) in radioligand therapy — genuinely frontier material, and the natural bridge to Chapter 36.

On conjugates.

• Reviews comparing antibody-drug conjugates with peptide-drug conjugates on penetration, half-life, payload capacity, and manufacture. Read these as trade-off analyses rather than as advocacy.
• The regulatory history of melphalan flufenamide — accelerated approval, confirmatory data, withdrawal — is worth following as a case study in what accelerated approval does and does not mean.

Tier 3 — Specialist and adjacent

• Primary medicinal chemistry literature on GnRH analog design: position-6 D-amino acid substitution, C-terminal modification, and the histamine-release problem that delayed the antagonists. Dense, and the best available illustration of why Chapter 33's toolkit exists.
• Depot formulation science — biodegradable microspheres, solid implants, supersaturated gels. This is the layer of engineering that turns an hours-long half-life into a months-long therapy, and it is almost never discussed in consumer peptide contexts.
• Long-term safety literature on androgen deprivation therapy: bone mineral density, metabolic syndrome, cardiovascular endpoints, and cognitive effects. Read enough of this to understand why the comparator matters.
• Health economics of radioligand therapy: manufacturing, isotope supply chains, delivery infrastructure, and access. A therapy that requires a nuclear medicine department is not equally available everywhere, and that is a real clinical fact rather than an administrative footnote.
• Literature on secondary hematologic malignancy after PRRT. Small numbers, long follow-up, and an instructive example of a risk that only becomes visible over years.

What to be careful with

Secondary coverage of radioligand therapy is where "progression-free survival" most reliably turns into "live longer." When you read a summary of NETTER-1 or VISION, check the endpoint before you check anything else.

Clinic and vendor material that groups approved oncology peptides together with unapproved wellness compounds under the heading "peptide therapy." The grouping is the argument, and the argument is Chapter 1's thesis in reverse: the word peptide carries no evidentiary weight, and treating it as though it does is precisely the error.

Anything counting PSMA therapy toward "peptide oncology" without noting that the ligands are mostly small molecules. It is a small imprecision that inflates a number which does not need inflating.

If you only do one thing

Pull the current prescribing information for lutetium Lu 177 dotatate and read the INDICATIONS AND USAGE section — the whole thing, slowly, out loud.

It is a few sentences. Count the qualifying clauses: tumor type, receptor status, patient population. Then write down, in your own words, the group of patients that sentence covers — and, separately, the groups it does not.

That exercise takes ten minutes and it teaches the chapter's most transferable lesson better than any amount of reading about it: an approval is a narrow, checkable statement about a specific population and a specific endpoint, not a general endorsement of a molecule. Once you have read one oncology label carefully, every vaguer claim you encounter afterward will look different.